The next cell therapy move takes Astra into neoantigens
For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
GSK’s “crown jewels” already look tarnished
As the company pulls Blenrep, questions about its future will only intensify.
Merck opens its mind to epigenetics with Imago buy
The purchase sets up another showdown with the group’s old rival, Bristol Myers Squibb, in LSD1 inhibition.
Ash 2022 preview – a new multiple myeloma mechanism makes a splash
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
